232 related articles for article (PubMed ID: 29337700)
1. Increased resistance to tissue plasminogen activator-induced fibrinolysis in healthy subjects from Thailand.
White NJ; Taflin N; Lim EB; Akaraborworn O
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):356-360. PubMed ID: 29337700
[TBL] [Abstract][Full Text] [Related]
2. The in-vitro effect of fibrinogen, factor XIII and thrombin-activatable fibrinolysis inhibitor on clot formation and susceptibility to tissue plasminogen activator-induced fibrinolysis in hemodilution model.
Shenkman B; Livnat T; Lubetsky A; Tamarin I; Budnik I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Jul; 23(5):370-8. PubMed ID: 22498982
[TBL] [Abstract][Full Text] [Related]
3. Southern copperhead venom enhances tissue-type plasminogen activator induced fibrinolysis but does not directly lyse human plasma thrombi.
Nielsen VG
J Thromb Thrombolysis; 2016 Jul; 42(1):33-7. PubMed ID: 26407681
[TBL] [Abstract][Full Text] [Related]
4. Variability of fibrinolytic activity in pregnant patients exposed to tissue plasminogen activator: an in vitro study utilizing rotational thromboelastometry.
Tran A; Katz D
Int J Obstet Anesth; 2024 Aug; 59():103994. PubMed ID: 38632015
[TBL] [Abstract][Full Text] [Related]
5. Validation of the time to attain maximal clot amplitude after reaching maximal clot formation velocity parameter as a measure of fibrinolysis using rotational thromboelastometry and its application in the assessment of fibrinolytic resistance in septic patients: a prospective observational study: communication from the ISTH SSC Subcommittee on Fibrinolysis.
Scarlatescu E; Kim PY; Marchenko SP; Tomescu DR
J Thromb Haemost; 2024 Apr; 22(4):1223-1235. PubMed ID: 38104723
[TBL] [Abstract][Full Text] [Related]
6. Fibrinolysis in patients with chemotherapy-induced thrombocytopenia and the effect of platelet transfusion.
Heubel-Moenen FCJI; Henskens YMC; Verhezen PWM; Wetzels RJH; Schouten HC; Beckers EAM
J Thromb Haemost; 2019 Jul; 17(7):1073-1084. PubMed ID: 31033178
[TBL] [Abstract][Full Text] [Related]
7. The in vivo effect of fibrinogen and factor XIII on clot formation and fibrinolysis in Glanzmann's thrombasthenia.
Shenkman B; Livnat T; Misgav M; Budnik I; Einav Y; Martinowitz U
Platelets; 2012; 23(8):604-10. PubMed ID: 22273510
[TBL] [Abstract][Full Text] [Related]
8. Effect of remote ischaemic conditioning on coagulation and fibrinolysis.
Kristiansen J; Grove EL; Rise N; Neergaard-Petersen S; Würtz M; Kristensen SD; Hvas AM
Thromb Res; 2016 May; 141():129-35. PubMed ID: 27018926
[TBL] [Abstract][Full Text] [Related]
9. Comparison of results obtained using clot-fibrinolysis waveform analysis and global fibrinolysis capacity assay with rotational thromboelastography.
Tsuchida T; Hayakawa M; Kumano O
Sci Rep; 2024 Mar; 14(1):7602. PubMed ID: 38556522
[TBL] [Abstract][Full Text] [Related]
10. Suggestions for global coagulation assays for the assessment of COVID-19 associated hypercoagulability.
van de Berg TW; Hulshof AM; Nagy M; van Oerle R; Sels JW; van Bussel B; Ten Cate H; Henskens Y; Spronk HMH;
Thromb Res; 2021 May; 201():84-89. PubMed ID: 33662799
[TBL] [Abstract][Full Text] [Related]
11. Recombinant tissue-type plasminogen activator-evoked hyperfibrinolysis is enhanced by acidosis and inhibited by hypothermia but still can be blocked by tranexamic acid.
Dirkmann D; Radü-Berlemann J; Görlinger K; Peters J
J Trauma Acute Care Surg; 2013 Feb; 74(2):482-8. PubMed ID: 23354242
[TBL] [Abstract][Full Text] [Related]
12. Rotation thromboelastometry analysis of clot formation and fibrinolysis in severe thrombocytopenia: effect of fibrinogen, activated prothrombin complex concentrate, and thrombin- activatable fibrinolysis inhibitor.
Shenkman B; Einav Y; Livnat T; Budnik I; Martinowitz U
Int J Lab Hematol; 2015 Aug; 37(4):521-9. PubMed ID: 25651468
[TBL] [Abstract][Full Text] [Related]
13. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
14. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
Hare TR; Gardell SJ
Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
[TBL] [Abstract][Full Text] [Related]
15. Plasma tissue-type plasminogen activator increases fibrinolytic activity of exogenous urokinase-type plasminogen activator.
Shenkman B; Livnat T; Budnik I; Tamarin I; Einav Y; Martinowitz U
Blood Coagul Fibrinolysis; 2012 Dec; 23(8):729-33. PubMed ID: 22918041
[TBL] [Abstract][Full Text] [Related]
16. Comparison of coagulation and fibrinolysis in Irish Wolfhounds and age-matched control dogs using tissue plasminogen activator-augmented viscoelastic testing.
Davis S; Fletcher DJ; Newman A; Brooks MB
J Vet Emerg Crit Care (San Antonio); 2024; 34(3):222-230. PubMed ID: 38775137
[TBL] [Abstract][Full Text] [Related]
17. Effects of colloid and crystalloid solutions on endogenous activation of fibrinolysis and resistance of polymerized fibrin to recombinant tissue plasminogen activator added ex vivo.
Mittermayr M; Streif W; Haas T; Fries D; Velik-Salchner C; Klingler A; Innerhofer P
Br J Anaesth; 2008 Mar; 100(3):307-14. PubMed ID: 18158312
[TBL] [Abstract][Full Text] [Related]
18. Rotational thromboelastometry as a biomarker for mortality - The Maastricht Intensive Care COVID cohort.
Hulshof AM; Nab L; van Rosmalen F; de Kok J; Mulder MMG; Hellenbrand D; Sels JWEM; Ten Cate H; Cannegieter SC; Henskens YMC; van Bussel BCT
Thromb Res; 2024 Feb; 234():51-58. PubMed ID: 38159324
[TBL] [Abstract][Full Text] [Related]
19. Quantification of Fibrinolysis Using Velocity Curves Measured with Thromboelastometry in Children with Congenital Heart Disease.
Faraoni D; Van der Linden P; Ducloy-Bouthors AS; Goobie SM; DiNardo JA; Nielsen VG
Anesth Analg; 2015 Aug; 121(2):486-91. PubMed ID: 26049780
[TBL] [Abstract][Full Text] [Related]
20. Factor XIII and tranexamic acid but not recombinant factor VIIa attenuate tissue plasminogen activator-induced hyperfibrinolysis in human whole blood.
Dirkmann D; Görlinger K; Gisbertz C; Dusse F; Peters J
Anesth Analg; 2012 Jun; 114(6):1182-8. PubMed ID: 22104068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
